Acrivon Therapeutics Inc (ACRV) Stock Price, Quote & News

Company Profile

Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 207 8979

Website: acrivon.com

Address:

480 Arsenal Way, Suite 100, Watertown, United States

Quaternity Jun. 16 at 6:20 PM

$ACRV so technically we hld the 200 MA hourly. Ive been saying this is a pretty important indicator for a few months now. Still a move 6 weeks out unless there is something beyond a technical suprise. 5.50

0 · Reply

ka1954 Jun. 13 at 7:41 PM

$ACRV just crazy that a stock can stay dead week after week

1 · Reply

Quaternity Jun. 13 at 7:33 PM

$ACRV did they say anything useful during their meeting today?

0 · Reply

lola269 Jun. 13 at 7:55 AM

$ACRV very

0 · Reply

ka1954 Jun. 12 at 7:51 PM

$ACRV man. this stock is just dead

1 · Reply

lola269 Jun. 12 at 10:44 AM

$ACRV

0 · Reply

Hazel1401 Jun. 9 at 2:10 PM

$ACRV $MLGO $SGN Key levels for big moves Acrv-1.44 Sgn-1.15 Mlgo-1.22

1 · Reply

Hazel1401 Jun. 9 at 1:39 PM

$ACRV $SGN $MLGO Betting the house on these from here.

0 · Reply

StickIt2Em Jun. 9 at 12:11 PM

$ACRV 1.40 pre-market, how we looking for the rest of the day/week

0 · Reply

Dani_G_German Jun. 6 at 1:33 AM

$ACRV

0 · Reply

Acrivon Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights

Apr 25, 2025, 8:00 AM EDT - 7 weeks ago

Acrivon Therapeutics to Reveal the Molecular Mechanisms Driving Strong Single-Agent Activity of ACR-2316, its AP3-Enabled Clinical Stage WEE1/PKMYT1 Inhibitor, at the AACR Annual Meeting 2025

Apr 7, 2025, 4:05 PM EDT - 2 months ago

Acrivon Therapeutics Appoints World-Renowned Oncology Key Opinion Leader and Clinical Investigator Mansoor Raza Mirza, M.D., as Chief Medical Officer

Mar 27, 2025, 5:44 PM EDT - 2 months ago

Acrivon Therapeutics Provides Program Updates and Fourth Quarter and Full Year 2024 Financial Results

Mar 19, 2025, 8:00 AM EDT - 3 months ago

Acrivon Therapeutics to Host Corporate R&D Event to Provide AP3 Platform Capabilities and Clinical ACR-368 and ACR-2316 Program Updates

Dec 12, 2024, 3:25 PM EST - 6 months ago

Acrivon Therapeutics: Endometrial Cancer Data Continues To Justify A Nascent Thesis

Oct 16, 2024, 4:00 PM EDT - 8 months ago

Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Oct 11, 2024, 8:00 AM EDT - 8 months ago

Acrivon Therapeutics Announces Initial Patient Dosing in Phase 1 Trial of ACR-2316, a Novel WEE1/PKMYT1 Inhibitor Designed Using AP3 for Superior Single-Agent Activity

Sep 18, 2024, 10:11 AM EDT - 9 months ago

Breaking Down Acrivon: Deep Dive Into Revenue, Profitability, And Prospects

Sep 14, 2024, 3:10 AM EDT - 9 months ago

Acrivon Therapeutics Reports Positive Endometrial Cancer Data from Ongoing ACR-368 Registrational Intent Phase 2 Study at ESMO, Advancement of ACR-2316 into Clinic Ahead of Timelines, and Progress on its AP3 Interactome for Proprietary Data Analysis

Jun 13, 2024, 2:00 PM EDT - 1 year ago

Acrivon Therapeutics: Can You Win In Clinical Trials With Selection Bias?

May 29, 2024, 8:00 AM EDT - 1 year ago

Acrivon Therapeutics to Present at the Jefferies Global Healthcare Conference

May 14, 2024, 8:00 AM EDT - 1 year ago

Acrivon Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights

Apr 24, 2024, 7:16 PM EDT - 1 year ago

Acrivon Therapeutics' shares climb 14% on plans to present cancer-test data

Apr 24, 2024, 4:01 PM EDT - 1 year ago

Acrivon Therapeutics Reports Initial Positive Clinical Data for ACR-368 and Pipeline Program Progress Today at Corporate R&D Event

Apr 16, 2024, 8:01 PM EDT - 1 year ago

Acrivon Therapeutics to Host Corporate R&D Event Highlighting AP3 and Pipeline Progress, Including Ongoing Prospective Validation of ACR-368 OncoSignature with Initial Phase 2 Data for ACR-368, and Preclinical Progress for ACR-2316

Apr 10, 2024, 8:00 AM EDT - 1 year ago

Acrivon Therapeutics Presents Data at AACR Annual Meeting Highlighting the Capabilities of Acrivon Predictive Precision Proteomics (AP3) for the Discovery of ACR-2316, a Novel, Selective WEE1/PKMYT1 Inhibitor, and the Identification of Actionable Resistan

Apr 9, 2024, 7:00 AM EDT - 1 year ago

Acrivon Therapeutics Announces $130 Million Private Placement Financing

Apr 3, 2024, 3:07 AM EDT - 1 year ago

What To Buy After You Sell The Russell 2000

AVUV IJR IWM IWN MLYS NXT SKWD

Mar 28, 2024, 8:00 AM EDT - 1 year ago

Acrivon Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

Mar 5, 2024, 4:30 PM EST - 1 year ago

Acrivon Therapeutics to Present Data at AACR Annual Meeting Demonstrating Power of Acrivon Predictive Precision Proteomics (AP3) Platform and its Internally-Discovered, Potent WEE1/PKMYT1 Development Candidate, ACR-2316

Feb 27, 2024, 8:00 AM EST - 1 year ago

Acrivon Therapeutics to Participate in a Panel Discussion at the TD Cowen 44th Annual Health Care Conference

Feb 6, 2024, 8:00 AM EST - 1 year ago

Acrivon Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Jan 12, 2024, 4:00 PM EST - 1 year ago

Acrivon Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nov 21, 2023, 8:00 AM EST - 1 year ago

Acrivon Therapeutics to Present at the Piper Sandler Annual Healthcare Conference

Nov 9, 2023, 8:01 AM EST - 1 year ago

Acrivon Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights

Oct 16, 2023, 8:00 AM EDT - 1 year ago

Acrivon Therapeutics Presents Data Demonstrating Capabilities of its AP3 Platform and ACR-368 OncoSignature Assay for Patient Responder Identification at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Sep 19, 2023, 4:32 PM EDT - 1 year ago

Acrivon Therapeutics to Highlight its ACR-368 OncoSignature Test, Used in Ongoing Phase 2 Study to Treat Patients Based on Predicted Sensitivity to Monotherapy with its CHK1/2 Inhibitor ACR-368, at the Upcoming AACR-NCI-EORTC International Conference on M

Sep 5, 2023, 4:05 PM EDT - 1 year ago

Acrivon Therapeutics Announces ACR-2316, a Novel Dual WEE1 and PKMYT1 Inhibitor Development Candidate, Designed Using Acrivon's AP3 Platform to Achieve Potent Single Agent Activity, as Demonstrated in Preclinical Studies

Aug 30, 2023, 8:00 AM EDT - 1 year ago

Acrivon Therapeutics to Participate in Two Investor Conferences in September

Aug 11, 2023, 7:00 AM EDT - 2 years ago

Acrivon Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights

Jun 22, 2023, 4:00 PM EDT - 2 years ago

Acrivon Therapeutics Announces the Appointment of Seasoned Biopharma Executive Charles Baum, M.D., Ph.D., a Recognized Leader in Clinical Precision Oncology, to its Board of Directors

Jun 2, 2023, 8:00 AM EDT - 2 years ago

Acrivon Therapeutics to Present at the Jefferies Healthcare Conference

May 9, 2023, 8:00 AM EDT - 2 years ago

Acrivon Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights

Apr 25, 2023, 8:00 AM EDT - 2 years ago

Acrivon Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference

Apr 18, 2023, 8:00 AM EDT - 2 years ago

Acrivon Therapeutics to Present at the Stifel 2023 Targeted Oncology Days Conference

Mar 28, 2023, 8:00 AM EDT - 2 years ago

Acrivon Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights

Mar 26, 2023, 9:53 AM EDT - 2 years ago

Acrivon: Precision-Testing Your Trial Patients Before Enrolment

Mar 6, 2023, 8:00 AM EST - 2 years ago

Acrivon Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare Conference

Nov 14, 2022, 10:16 PM EST - 2 years ago

Acrivon Therapeutics Announces Pricing of Initial Public Offering

Nov 3, 2022, 7:52 AM EDT - 2 years ago

Acrivon Therapeutics sets IPO price range

Oct 19, 2022, 11:50 AM EDT - 2 years ago

Acrivon Therapeutics Begins U.S. IPO Rollout

Quaternity Jun. 16 at 6:20 PM

0 · Reply

ka1954 Jun. 13 at 7:41 PM

$ACRV just crazy that a stock can stay dead week after week

1 · Reply

Quaternity Jun. 13 at 7:33 PM

$ACRV did they say anything useful during their meeting today?

0 · Reply

lola269 Jun. 13 at 7:55 AM

$ACRV very

0 · Reply

ka1954 Jun. 12 at 7:51 PM

$ACRV man. this stock is just dead

1 · Reply

lola269 Jun. 12 at 10:44 AM

$ACRV

0 · Reply

Hazel1401 Jun. 9 at 2:10 PM

$ACRV $MLGO $SGN Key levels for big moves Acrv-1.44 Sgn-1.15 Mlgo-1.22

1 · Reply

Hazel1401 Jun. 9 at 1:39 PM

$ACRV $SGN $MLGO Betting the house on these from here.

0 · Reply

StickIt2Em Jun. 9 at 12:11 PM

$ACRV 1.40 pre-market, how we looking for the rest of the day/week

0 · Reply

Dani_G_German Jun. 6 at 1:33 AM

$ACRV

0 · Reply

FeliciaMath Jun. 5 at 1:29 PM

bought $ACRV at 1.26

0 · Reply

Dani_G_German Jun. 5 at 1:26 PM

$ACRV start of a reversal

0 · Reply

FeliciaMath Jun. 5 at 4:54 AM

i may buy $ACRV tomorrow

0 · Reply

Havyanksa Jun. 5 at 1:15 AM

$ACRV the selling overhang is officially done! Per 13G filing this afternoon, Perceptive Advisors (1 or 2 largest shareholder), disclosed they’s out. Perhaps this ACRV will rocket higher to trade at only 50% of net cash (which would be $2.50/share). ;) seriously though, overhang is done

0 · Reply

ALZTrading Jun. 5 at 12:45 AM

$ACRV perceptive advisors has completely exited their holding based on the 13G released today.

0 · Reply

ALZTrading Jun. 4 at 5:06 PM

$ACRV keep the momentum up!

0 · Reply

Quaternity Jun. 4 at 3:36 PM

$ACRV all of my $MULN gains today are going to $ACRV One key to trading is ride the adenaline and select a sleeper for the next cycles move.

0 · Reply

valueforme Jun. 3 at 10:15 PM

$ACRV Weird one. Need to do some DD

0 · Reply

Quaternity Jun. 3 at 6:27 PM

$ACRV well this is going to probably be the first close over the hourly moving average in several weeks so that does say something. I still think this move is a couple of months out however

0 · Reply

Dani_G_German Jun. 3 at 6:26 PM

$ACRV feels different this time 🤞

0 · Reply

Wallymarket Jun. 3 at 2:55 PM

$NIVF they manipulated the stock yesterday I was scared to load 52wl thinking something was going on but na just pure manipulation $ACRV load and hold for breakthrough news they have 160m in cash run away till 2027 $TIVC waiting on FDA and data update $INTS presentation news to be released $GBIO Thursday presentation 👍 I would rather swing than chase you do your own dd on each 👍

1 · Reply

Wallymarket Jun. 3 at 2:46 PM

$LYRA you want a lyra move you have to be patiently holding check $ACRV and $TIVC one waiting on breakthrough news and one waiting on FDA news missed $RSLS kept selling it before RS but not missing these $GBIO another 1

0 · Reply

Market Cap	37.63M
Revenue (ttm)	0.00
Net Income (ttm)	-80.56M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	277,600
Avg Vol	895,598
Day's Range	N/A - N/A
Shares Out	31.36M
Stochastic %K	36%
Beta	1.55
Analysts	Strong Sell
Price Target	$12.00